In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.
Agreement enables Hims & Hers users to access branded Ozempic 0.5–2 mg and Wegovy injectable 0.25–2.4 mg plus oral strengths 1.5–25 mg. Hims & Hers will cease marketing compounded GLP-1 products and ...
In today's Pharma Pulse, the NCPA warns of a severe cash flow crisis for independent pharmacies under the Medicare Drug Price ...
Key Takeaways. Section 804 creates a legal pathway for states and tribes to import certain Canadian prescription drugs, contingent on demonstrable consumer savings and adherence t ...
In today’s Pharma Pulse, Eli Lilly has launched the Employer Connect platform broadening access to Zepbound for U.S. workers, ...
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated ...
A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
Thermal testing can make or break cold chain performance. Join this webinar to learn proven best practices that help eliminate blind spots, validate designs, and protect temperature-sensitive ...
Thirty telehealth firms received warning letters for illegal promotion of compounded semaglutide/tirzepatide, reflecting an expanded enforcement tempo that now ...
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results